WebSep 9, 2024 · GRAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. WebContact Information Website www.grail.com Ownership Status Acquired/Merged (Operating Subsidiary) Financing Status Formerly VC-backed Primary Industry Biotechnology Other Industries Clinics/Outpatient Services Diagnostic Equipment Parent Company Illumina Primary Office 1525 O'Brien Drive Menlo Park, CA 94025 United States +1 (833) 000-0000
Illumina buys spinout Grail, betting $8B on the future of cancer ...
WebAug 6, 2024 · In the first quarter, Illumina’s s ales soared about 27% year-over-year to a record $1 billion, up from roughly 20% YOY during the previous quarter. What’s more, Illumina was profitable,... WebSep 17, 2024 · That’s a bit more than double the IPO price of $120. It also means that there was no way for normal investors to pick up shares anywhere between $120 and $245 a share. And the stock went as high … dickerson chicago
Grail Files for IPO Ahead of Launching Multi-Cancer Liquid Biopsy ...
WebSep 9, 2024 · L iquid biopsy company Grail has filed for a $100 million initial public offering, according to SEC documents. The company, which has raised about $2 billion from … WebApr 3, 2024 · The Federal Trade Commission ordered Monday that biotech firm Illumina ( ILMN) must unwind its $7 billion purchase of the cancer-testing startup Grail. ILMN stock fell on the news. Sorry, the... WebSep 21, 2024 · Dive Brief: Illumina has agreed to acquire Grail in an $8 billion deal that could establish the sequencing giant as a leading player in the growing race to use blood-based tests known as liquid biopsies to catch cancers early.; Grail spun out of Illumina in 2016 and raised $2 billion to back its work. Long-rumored to be considering an initial … citizens bank new ulm login